Safety and performance of contemporary press-fit titanium osseointegration implants in lower extremity amputation : a five-year follow-up study.

IF 4.9 1区 医学 Q1 ORTHOPEDICS
Robin Atallah, Elmer Rutjes, Jan P M Frölke, Ruud A Leijendekkers
{"title":"Safety and performance of contemporary press-fit titanium osseointegration implants in lower extremity amputation : a five-year follow-up study.","authors":"Robin Atallah, Elmer Rutjes, Jan P M Frölke, Ruud A Leijendekkers","doi":"10.1302/0301-620X.107B4.BJJ-2024-0754.R1","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Treatment using bone-anchored prostheses (BAPs) with press-fit femoral osseointegration implants (OIs) has been used in patients with lower limb amputations for more than two decades. The development of these OIs has enabled treatment in patients with a short transfemoral and a transtibial amputation. The aim of this follow-up study was to report the safety of this treatment at five years postoperatively, the prosthesis wearing time (PWT), and health-related quality of life (HRQoL).</p><p><strong>Methods: </strong>All consecutive patients undergoing treatment between March 2015 and June 2018 using one of three different OIs were eligible for inclusion. A total of 90 patients were included, of whom 14 were lost to follow-up, leaving 76 available for analysis. The curved- or gamma-osseointegration femoral implant (OFI-C, OFI-Y) was used in patients with a mid-diaphyseal or short transfemoral amputation, respectively. The osseointegration tibial implant (OTI) was used in those with a transtibial amputation. The adverse events which were evaluated included infection (soft-tissue, bone, implant), stoma-related complications, aseptic loosening, implant breakage, periprosthetic fracture, and complications between surgical stages. The functional outcomes which were assessed included the Questionnaire for Persons with a Transfemoral Amputation (Q-TFA)-Prosthetic Use Score (PUS) and the Global Score (GS), for PWT and HRQoL, respectively.</p><p><strong>Results: </strong>A 94.2% implant survival was achieved at five years (OFI-C = 93.8%, OFI-Y = 93.3%, OTI = 95.5%); five implants were removed. Overall, 27 patients (36%) had a total of 56 infections, 53 (95%) of which were infections of the soft-tissues. Septic loosening occurred in three patients (4%, OFI-C = 2, OTI = 1), resulting in removal of the implant in two. The infection/implant-year ratio was 0.09, 0.16, and 0.24 for OFI-C, OFI-Y and OTI, respectively. Periprosthetic fracture occurred in four patients (5%, all OFI-C); all were treated surgically, three with fixation, one with removal. One patient had asymptomatic radiological evidence of partial aseptic loosening; this was managed conservatively. Stoma-related problems required surgery on 26 occasions, mostly in patients treated with an OFI-Y. The implant was removed in two patients (2.6%) due to unexplained pain. Complications between surgical stages were mostly surgical site infections, requiring bringing forward stage 2 on seven occasions. Baseline Q-TFA-PUS and GS scores increased significantly in all patients, and also when stratified per type of implant with the passage of time.</p><p><strong>Conclusion: </strong>Contemporary press-fit titanium OIs, when used in lower limb amputations, result in acceptable rates of survival and safety, with considerable improvements in functional outcomes.</p>","PeriodicalId":48944,"journal":{"name":"Bone & Joint Journal","volume":"107-B 4","pages":"486-494"},"PeriodicalIF":4.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone & Joint Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1302/0301-620X.107B4.BJJ-2024-0754.R1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Treatment using bone-anchored prostheses (BAPs) with press-fit femoral osseointegration implants (OIs) has been used in patients with lower limb amputations for more than two decades. The development of these OIs has enabled treatment in patients with a short transfemoral and a transtibial amputation. The aim of this follow-up study was to report the safety of this treatment at five years postoperatively, the prosthesis wearing time (PWT), and health-related quality of life (HRQoL).

Methods: All consecutive patients undergoing treatment between March 2015 and June 2018 using one of three different OIs were eligible for inclusion. A total of 90 patients were included, of whom 14 were lost to follow-up, leaving 76 available for analysis. The curved- or gamma-osseointegration femoral implant (OFI-C, OFI-Y) was used in patients with a mid-diaphyseal or short transfemoral amputation, respectively. The osseointegration tibial implant (OTI) was used in those with a transtibial amputation. The adverse events which were evaluated included infection (soft-tissue, bone, implant), stoma-related complications, aseptic loosening, implant breakage, periprosthetic fracture, and complications between surgical stages. The functional outcomes which were assessed included the Questionnaire for Persons with a Transfemoral Amputation (Q-TFA)-Prosthetic Use Score (PUS) and the Global Score (GS), for PWT and HRQoL, respectively.

Results: A 94.2% implant survival was achieved at five years (OFI-C = 93.8%, OFI-Y = 93.3%, OTI = 95.5%); five implants were removed. Overall, 27 patients (36%) had a total of 56 infections, 53 (95%) of which were infections of the soft-tissues. Septic loosening occurred in three patients (4%, OFI-C = 2, OTI = 1), resulting in removal of the implant in two. The infection/implant-year ratio was 0.09, 0.16, and 0.24 for OFI-C, OFI-Y and OTI, respectively. Periprosthetic fracture occurred in four patients (5%, all OFI-C); all were treated surgically, three with fixation, one with removal. One patient had asymptomatic radiological evidence of partial aseptic loosening; this was managed conservatively. Stoma-related problems required surgery on 26 occasions, mostly in patients treated with an OFI-Y. The implant was removed in two patients (2.6%) due to unexplained pain. Complications between surgical stages were mostly surgical site infections, requiring bringing forward stage 2 on seven occasions. Baseline Q-TFA-PUS and GS scores increased significantly in all patients, and also when stratified per type of implant with the passage of time.

Conclusion: Contemporary press-fit titanium OIs, when used in lower limb amputations, result in acceptable rates of survival and safety, with considerable improvements in functional outcomes.

当代加压钛骨整合植入物在下肢截肢中的安全性和性能:一项为期五年的随访研究。
目的:使用骨锚定假体(BAPs)和加压股骨骨整合植入物(OIs)治疗下肢截肢患者已有20多年的历史。这些oi的发展使短经股骨和经胫骨截肢患者的治疗成为可能。本随访研究的目的是报告该治疗在术后5年的安全性、假体佩戴时间(PWT)和健康相关生活质量(HRQoL)。方法:所有在2015年3月至2018年6月期间连续接受三种不同OIs治疗的患者均符合纳入条件。共纳入90例患者,其中14例失去随访,剩下76例可供分析。弯曲型或γ -骨整合型股骨植入物(OFI-C, OFI-Y)分别用于骨干中段或短段经股截肢患者。骨整合胫骨种植体(OTI)用于经胫骨截肢患者。评估的不良事件包括感染(软组织、骨、种植体)、造口相关并发症、无菌性松动、种植体断裂、假体周围骨折以及手术阶段之间的并发症。评估的功能结果包括经股截肢者问卷(Q-TFA)-假肢使用评分(PUS)和整体评分(GS),分别用于PWT和HRQoL。结果:5年种植体成活率为94.2% (OFI-C = 93.8%, OFI-Y = 93.3%, OTI = 95.5%);5个植入物被移除。27例(36%)患者共56例感染,其中53例(95%)为软组织感染。3例患者(4%,OFI-C = 2, OTI = 1)发生脓毒性松动,2例患者植入物被取出。OFI-C、OFI-Y和OTI的感染/种植年比分别为0.09、0.16和0.24。4例患者发生假体周围骨折(5%,均为OFI-C);所有患者均手术治疗,3例固定,1例切除。1例患者有部分无菌性松动的无症状放射学证据;这是保守的管理。与造口有关的问题需要手术26次,大多数患者接受了OFI-Y治疗。2例(2.6%)患者由于不明原因的疼痛而移除植入物。手术阶段之间的并发症主要是手术部位感染,7次需要提前2期。随着时间的推移,所有患者的基线Q-TFA-PUS和GS评分均显著增加,按种植体类型分层时也是如此。结论:当代加压式钛OIs用于下肢截肢时,可获得可接受的生存率和安全性,并显著改善功能预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Bone & Joint Journal
Bone & Joint Journal ORTHOPEDICS-SURGERY
CiteScore
9.40
自引率
10.90%
发文量
318
期刊介绍: We welcome original articles from any part of the world. The papers are assessed by members of the Editorial Board and our international panel of expert reviewers, then either accepted for publication or rejected by the Editor. We receive over 2000 submissions each year and accept about 250 for publication, many after revisions recommended by the reviewers, editors or statistical advisers. A decision usually takes between six and eight weeks. Each paper is assessed by two reviewers with a special interest in the subject covered by the paper, and also by members of the editorial team. Controversial papers will be discussed at a full meeting of the Editorial Board. Publication is between four and six months after acceptance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信